ResQ Biotech

Description

ResQ Biotech builds a living-cell discovery platform that biosynthesizes and functionally screens ultra-large libraries to identify therapeutics that rescue pathogenic protein misfolding for neurodegenerative and systemic diseases.

Related

• NucleraNuclera builds and supplies eProtein Discovery systems, cartridges, reagents and services for multiplex cell-free protein screening used by…
• SpliceBioSpliceBio builds protein splicing–based genetic medicines and develops therapeutics for diseases caused by mutations in large genes,…
• BioArcticBioArctic develops therapeutics and related technologies for neurodegenerative disorders, focusing on disease-modifying treatments and…
• BraineverBrainever develops hEN1 and hOTX2 homeoprotein drug candidates intended to limit neurodegenerative disease progression by preventing…
• Anacalypsis TherapeuticsAnacalypsis Therapeutics creates precision gene- and pathway-based therapeutic strategies, biomarkers, and genetically linked targets to…
• Herantis PharmaHerantis Pharma develops disease-modifying therapies designed to stop or reverse progression of neurodegenerative diseases, applying drug…
• Molecular PartnersMolecular Partners develops DARPin therapeutics, including Radio-DARPins and logic-gated Switch-DARPins, to target DLL3, FAP x CD40, and…
• ALLOXALLOX uses high-throughput experiments with genetics and AI to learn biophysical parameters of protein function, supporting systematic…
• HealxHealx builds AI-driven drug discovery and development tools and therapies for rare disease patients, applying AI across discovery,…